Glucagon-like peptide-1 (GLP-1) has been shown to bind to the posterior pituitary in the rat. We examined GLP-1 binding sites in human postmortem and rat pituitaries. Dense [ 125 I]GLP-1 binding was seen in both human and rat posterior pituitary. In rat neurointermediate lobe membranes the binding site showed a K d of 0.2 Ϯ 0.01 nM and a binding capacity of 600 Ϯ 33 fmol/mg protein (n ϭ 3). In human pituitary membranes the binding site showed a K d of 0.82 Ϯ 0.05 nM and a binding capacity of 680 Ϯ 93 fmol/mg protein (n ϭ 3). Chemical cross-linking showed a relative mol wt for the receptorligand complex of 73,100 Ϯ 1,400 (n ϭ 3) in man and 59,300 Ϯ 900 (n ϭ 3) in rat. GLP-1 (1 M) failed to increase cAMP levels measured in rat neurointermediate lobes, whereas pituitary adenylate cyclase-activating polypeptide (100 nM) increased cAMP from a basal level of 14 Ϯ 1 to 80 Ϯ 4 pmol/neurointermediate lobe⅐15 min (n ϭ 5; P Ͻ 0.01). G LUCAGON-LIKE PEPTIDE-1-(7-36) amide (GLP-1), a member of the glucagon/secretin family of peptides, is derived from the tissue-specific posttranslational processing of proglucagon in intestinal L cells and the central nervous system (CNS) (1). It is released from the gut into the circulation after meals (2), potently stimulates glucoseinduced insulin secretion (3, 4), and inhibits glucagon secretion (5). GLP-1 also inhibits pentagastrin-stimulated gastric acid secretion (6) and gastric emptying (7) and increases arterial blood pressure and heart rate in rats (8).
3) in rat. GLP-1 (1 M) failed to increase cAMP levels measured in rat neurointermediate lobes, whereas pituitary adenylate cyclase-activating polypeptide (100 nM) increased cAMP from a basal level of 14 Ϯ 1 to 80 Ϯ 4 pmol/neurointermediate lobe⅐15 min (n ϭ 5; P Ͻ 0.01). GLP-1 (up to 1 M) did not affect the pituitary adenylate cyclaseactivating polypeptide-stimulated cAMP levels. GLP-1 (up to 1 M) also did not stimulate release of vasopressin or oxytocin from isolated rat neurointermediate lobes. The posterior pituitary shows the highest density of GLP-1-binding sites yet seen, but their function and signal transduction mechanism remain unknown. G LUCAGON-LIKE PEPTIDE-1-(7-36) amide (GLP-1), a member of the glucagon/secretin family of peptides, is derived from the tissue-specific posttranslational processing of proglucagon in intestinal L cells and the central nervous system (CNS) (1) . It is released from the gut into the circulation after meals (2) , potently stimulates glucoseinduced insulin secretion (3, 4) , and inhibits glucagon secretion (5) . GLP-1 also inhibits pentagastrin-stimulated gastric acid secretion (6) and gastric emptying (7) and increases arterial blood pressure and heart rate in rats (8) .
Binding sites for GLP-1 have been demonstrated on human pancreatic ␤-cells, rat insulinoma cell lines, lung, stomach, certain brain regions, heart, and kidney (2) . The complementary DNAs encoding the human (9) and rat (10) pancreatic islet GLP-1 receptor have been cloned. The rat GLP-1 receptor consists of 463 amino acids, and its structure includes seven transmembrane regions. Rat and human cloned GLP-1 receptors are characterized by a high affinity for the lizard venom peptide, exendin-4, and a potent antagonist effect of the exendin fragment, exendin-(9 -39) (11) . These receptors belong to the subclass of the G proteincoupled receptor family that includes receptors for glucagon, secretin, vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide (PACAP), PTH, and calcitonin (10) . All of these G protein-linked receptors have been shown to be coupled, via G s (the stimulatory G protein), to the activation of membrane-bound adenylyl cyclase. In cells transfected with the cloned rat or human GLP-1 receptors, agonist binding also primarily stimulates adenylyl cyclase (10, 12) , but mechanisms involving increases in intracellular calcium have also been described (13, 14) . GLP-1 has been shown to increase intracellular cAMP in insulinoma cell lines (15) . We have shown that GLP-1 increased cAMP levels in the GT 1 -7 mouse hypothalamic LHRH-secreting cell line (16) and in the mouse ␣TSH pituitary thyrotroph-like cell line (17) . However, the cloned GLP-1 receptors may not be the only GLP-1 receptors. GLP-1 binding and effects have been demonstrated in human and rat adipose tissue (18, 19) and skeletal muscle (20) in the absence of messenger RNA for the cloned receptors. Interestingly, GLP-1 has been associated with either no change in cAMP levels (20, 21) or a decrease in cAMP levels (22, 23) in both of these systems.
In the CNS, the presence of GLP-1-like immunoreactive (-IR) cell bodies has been demonstrated only in the nucleus of solitary tract and the ventral and dorsal parts of the medullary reticular nucleus (24) . GLP-1-IR nerve fibers are found throughout the brain, but the highest concentrations are in the hypothalamus and brainstem (25) . GLP-1-IR has not been detected in the pituitary (26) . Recent studies indicate a physiological role for GLP-1 as a central neurotransmitter or neuromodulator. We and others have demonstrated that intra-cerebroventricular (icv) administration of GLP-1 in rats inhibits food intake (27) (28) (29) . Intracerebroventricular injection of GLP-1 in rats also inhibits basal water intake and stimulates urinary excretion of water and sodium. In rats both icv and ip administrations of GLP-1 inhibit basal and angiotensin II-induced water drinking (28, 29) .
These studies suggested that GLP-1 has a potential physiological role in the CNS control of drinking behavior. Specific binding sites for GLP-1 have been demonstrated in the CNS, in particular in the paraventricular nucleus, central nucleus of the amygdala, and anterodorsal thalamic nucleus (25, 27, 30) . Goke et al. recently demonstrated specific GLP-1-binding sites on the posterior lobe of rat pituitary (31) . The presence of high density GLP-1-binding sites in the rat posterior pituitary suggests that this peptide may play a direct (via circulating GLP-1) or an indirect (via hypothalamic GLP-1 and hypothalamic receptors) role in the control of posterior pituitary hormone secretion. The posterior pituitary consists mainly of glial cells, termed pituicytes, and of unmyelinated nerve fibers and axon terminals of neurons whose cell bodies reside primarily in supraoptic nucleus and paraventricular nucleus (32) . These hypothalamo-neurohypophyseal fibers deliver the two primary posterior pituitary hormones, arginine vasopressin (AVP) and oxytocin (OT). In addition to AVP and OT, many other neuropeptides, including endothelin, neuropeptide Y, and PACAP, have been located within these neurons. PACAP has been shown to stimulate both cAMP formation and AVP secretion in rat posterior pituitary (33) . Interestingly, direct in vitro addition of GLP-1 to isolated posterior pituitaries had no effect on AVP release, but slightly increased OT release (34) . It might have been expected that GLP-1 would, like PACAP, increase cAMP and stimulate AVP release.
Here, using a combination of receptor autoradiography and membrane binding assays, we confirm the presence of GLP-1-binding sites in rat neurointermediate lobe membranes and demonstrate for the first time GLP-1 binding in human pituitary. We characterized these sites with respect to binding parameters, cAMP generation, and mol wt and compared them with the cloned GLP-1 receptors. We also examined the effect of GLP-1 on AVP or OT release in isolated rat neurointermediate lobes.
Materials and Methods Materials
GLP-1 and the exendin peptides were synthesized using an automated peptide synthesizer and were checked for correct molecular weight by mass spectroscopy. The batch of GLP-1 used in this study was shown to be active by demonstrating a 5-fold stimulation of cAMP in a rat insulinoma cell line (RIN m5F) well known for showing GLP-1-stimulated adenylyl cyclase activity (15) . PACAP-(1-38) was supplied by Peptide Products (Southampton, UK). Na 
Iodination of GLP-1
GLP-1 was iodinated by the chloramine-T method, and monoiodinated peptide was purified by HPLC as described previously (17) . Peak fractions were assayed for receptor-binding activity, and those with high specific binding were aliquoted, freeze-dried, and stored at Ϫ20 C. The specific activity of the label, determined by RIA (4), was 50 Ϯ 4 becquerels (Bq)/fmol (n ϭ 6).
Animals and tissues
Adult male Wistar rats (BSU, Hammersmith Hospital, UK), weighing 200 -250 g, were housed in wire-bottomed cages with ad libitum access to food and water. All procedures were licensed by the British Home Office under the Animals (Scientific Procedures) Act 1986. Animals were killed by CO 2 asphyxiation, and the brain, pituitary, and other tissues were rapidly removed and either frozen in liquid nitrogen and stored at Ϫ80 C before membrane preparation or used immediately for receptor autoradiography or static incubation of pituitary. For rat hypothalamic membrane preparations the rat hypothalamus was dissected before freezing as previously described (35 Membranes were prepared by the method of homogenization and differential centrifugation as described previously (36) . Briefly, tissues were homogenized in ice-cold 50 mm HEPES buffer (pH 7.4; containing 0.25 m sucrose; 10 g/ml soybean trypsin inhibitor; 0.5 g/ml pepstatin, leupeptin, and antipain; 0.1 g/ml benzamidine; 0.1 g/ml bacitracin; and 30 g/ml aprotinin), with an Ultra Turrax homogenizer (Merck & Co., Inc.). For the human pituitary membranes one pituitary was used for each preparation. The homogenate was centrifuged for 10 min at 1,500 ϫ g, and the supernatant was centrifuged for 1 h at 100,000 ϫ g at 4 C. The pellet was resuspended in the same buffer without sucrose and centrifuged for 1 h at 100,000 ϫ g at 4 C. Using a hand-held glass-Teflon homogenizer, membranes were resuspended in the same buffer to a final protein concentration of 3-10 mg/ml, as measured by the biuret method and stored at Ϫ80 C.
In vitro receptor autoradiography
After removal from the skull, the whole rat pituitary gland was placed onto a small piece of rat tongue to aid cutting of sections and then embedded in OCT compound (Raymond Lamb, London, UK) on a cork block. Sections were snap-frozen in isopentane (cooled in liquid nitrogen for 20 sec) and stored at Ϫ80 C. For the human whole pituitary, frozen tissue was embedded in OCT compound on a cork block and placed into the cryostat (Ϫ20 C; cryostat microtome, Bright Instrument Co., Huntingdon, UK) to enable the OCT compound to freeze. Serial 15-m cryostat sections were thaw-mounted on gelatin/chrome alum-subbed slides (37) . These were dried under vacuum at 4 C, wrapped in clingfilm, and stored at Ϫ20 C. On the day of use, stored slides were allowed to equilibrate at room temperature before removal of cling-film. Sections were preincubated in ice-cold 25 mm HEPES assay buffer (pH 7.4) containing 2 mm MgCl 2 , 0.1% bacitracin, 0.05% Tween-20, 0.1 mm diprotin A (Ile-Pro-Ile, Sigma), and 1% BSA for 20 min. Excess liquid was drained from the slides, which were then incubated in assay buffer containing [
125 I]GLP-1 (1000 Bq/ml) for 90 min at 22 C. Nonspecific binding was determined in the presence of 200 nm unlabeled GLP-1. After incubation, the slides were washed four times for 30 sec each time in ice-cold assay buffer, rinsed once in ice-cold distilled water, and dried overnight at 4 C under vacuum. This was followed by dry apposition to 3 H-labeled Hyperfilm (Amersham International) in a light-proof cassette that was stored at Ϫ80 C for 7-10 days before developing. Hematoxylin and eosin stain (H&E) was employed to distinguish between the anterior and posterior portions of the pituitary.
GLP-1 receptor binding studies
GLP-1 binding studies were essentially carried out as previously described (16) . In brief, rat neurointermediate lobe (50 g) or anterior lobe (100 g) membranes were incubated for 90 min in silanized polypropylene tubes together with [
125 I]GLP-1 (750 Bq, 30 pm) at room temperature (20 C) in binding buffer for autoradiography in a final assay volume of 0.5 ml. Bound and free label were separated by rapid filtration of the entire incubation mixture through a glass-fiber filter (GF/B, Whatman, Clifton, NJ), presoaked for 24 h in 0.3% polyethylenimine, under reduced pressure using a Brandel M24 cell harvester (Biomedical Research Instruments, Inc., Gaithersburg, MD). The filters were washed six times with 2 ml ice-cold 50 mm Tris-HCl buffer (pH 7.4) and dried, and the radioactivity bound to the filter was measured using a ␥-counter. Specific binding was calculated as the difference between the amount of [ 125 I]GLP-1 bound in the absence (total) and presence (nonspecific) of 200 nm unlabeled peptide. To determine the time taken to achieve equilibrium binding, assays were terminated at varying time points (from 2-240 min), and specific binding was calculated. Equilibrium competition curves were constructed with increasing amounts of unla- 
Chemical cross-linking of receptor-ligand complexes
Chemical cross-linking and SDS-PAGE were performed essentially as previously described (38) . In brief, membranes (200 g) were incubated with 10,000 Bq (0.3 nm) [
125 I]GLP-1with or without unlabeled GLP-1 (1 m) as described above, but bound label was separated from free label by centrifugation at 15,000 ϫ g for 2 min at 4 C. Pellets were washed with 0.5 ml binding buffer at 4 C. The cross-linking reaction was initiated by the addition of BSOCOES in Me 2 SO to a final concentration of 3 mm. After incubation for 30 min at 4 C, the reaction was quenched by washing the membranes twice with 500 l ice-cold 50 mm Tris-HCl (pH 7.4). Membranes were recovered by centrifugation, and the pellet was taken up in 40 l Laemmli sample buffer (39) . Protein was separated on a 4% acrylamide stacking-10% acrylamide resolving gel. After drying, the gels were exposed to Kodak X-Omat film (IBI, Cambridge, UK) for up to 2 weeks at Ϫ80 C using an image-intensifying screen.
Effects of GLP-1 on cAMP in the rat neurointermediate lobe
Adult male Wistar rats (200 -250 g) were killed by CO 2 asphyxiation, and the neurointermediate lobes were immediately dissected free of the anterior pituitaries. The neurointermediate lobes were transferred to a Krebs-Ringer (KRB) bicarbonate solution, pH 7.4 (120 mm NaCl, 5 mm KCl, 2.6 mm CaCl 2 , 1.2 mm KH 2 PO 4 , 0.7 mm MgSO 4 , 22.5 mm NaHCO 3 , 1.8 g/liter BSA, and 0.1 g/liter ascorbic acid). Before starting the experiment, the neurointermediate lobes were singly immersed in wells containing 1 ml fresh KRB and maintained at 37 C for 60 min in 95% O 2 -5% CO 2 . Neurointermediate lobes were washed twice in KRB and exposed for 15 min to KRB buffer containing 2 mm isobutylmethylxanthine (IBMX) alone or with GLP-1 (1-1000 nm) or forskolin (100 m). Alternatively, to investigate any inhibitory effect that GLP-1 might have on cAMP formation, neurointermediate lobes were exposed for 15 min to KRB buffer containing 2 mm IBMX alone or with PACAP-(1-38) (100 and 1000 nm) or PACAP-(1-38) (100 nm) plus GLP-1 (10 and 100 nm). PACAP-(1-38) is a known stimulator of cAMP in the posterior pituitary (33). The neurointermediate lobes were then individually homogenized in 500 l 75% ethanol containing 16 mm HCl, using a hand-held glassTeflon homogenizer and extracted overnight at Ϫ20 C. The samples were dried by rotary evaporation, and cAMP concentrations were measured using a cAMP RIA kit (NEN Life Science Products, Stevenage, UK).
Effect of GLP-1 on neurohypophyseal hormone secretion in isolated neurointermediate lobes
Neurointermediate lobes were dissected from adult male Wistar rats (200 -250 g) as described above. They were then singly immersed in wells containing 1 ml fresh KRB and maintained at 37 C in 95% O 2 -5% CO 2 . Before starting the experiments, the neurointermediate lobes were equilibrated for 60 min in KRB. Tissues were then exposed for 15 min to KRB (control) or for 15 min to KRB together with GLP-1 at the required concentration (1-1000 nm) . To check that the neurointermediate lobes could be stimulated, the tissues were exposed for 15 min to KRB containing 56 mm KCl and 69 mm NaCl to maintain medium osmolarity (high K ϩ depolarization treatment). Medium was collected after each period of stimulation and stored at Ϫ20 C until AVP and OT levels were measured by specific RIA (reagents and methods from Biogenesis, Poole, UK). The effects of various doses of GLP-1 on basal and 56 mm K ϩ -evoked release of AVP and OT in each experiment were estimated by comparing the mean secretions from six neurointermediate lobes.
Statistical analysis
Results are shown as the mean Ϯ se. For the cAMP and posterior pituitary hormone secretion experiments data were compared by repeated measures ANOVA with subsequent post-hoc Tukey's tests (Systat, Evanston, IL) between control and experimental groups, with P Ͻ 0.05 considered to be statistically significant. For binding data, analysis of one-site vs. two-site competition curves was performed using the F test, with two-component fits considered significant at P Ͻ 0.05. (Fig. 1C) . Investigation into the distribution of [
Results

Receptor autoradiography of [ 125 I]GLP-1 binding in the pituitary
125 I]GLP-1-binding sites in the human pituitary revealed dense localized binding in one discrete region, with low specific binding in the remainder of the tissue (Fig.  1, E and F) . Histological staining of the same slices (Fig. 1, A and D) using H&E confirmed that the area displaying high specific binding sites for [
125 I]GLP-1 was indeed the neural tissue of the posterior lobe, at least in the rat. Analysis of the stained sections revealed that hematoxylin had stained the nuclei of the anterior pituitary cells, whereas no such staining was visible in the nerve endings of the posterior pituitary (Fig. 1, A and D) . The intermediate lobe can be seen on the rat H&E-stained section in between the posterior and anterior pituitary and does not show any GLP-1 binding (Fig. 1,  A and B) . In the human pituitary, the relatively small intermediate lobe is not clearly visible (Fig. 1D) . In one experiment to confirm the receptor autoradiography, we compared [
125 I]GLP-1 binding in anterior and neurointermediate lobe membranes from the same animals with membrane preparation on the same day. Specific binding in the anterior membranes was very low (1.0 Ϯ 0.3 fmol bound/mg membrane protein; n ϭ 5 measurements) compared with that in the neurointermediate lobes (16.1 Ϯ 0.7 fmol bound/mg membrane protein; n ϭ 5 measurements). The level of binding in the anterior pituitary was not sufficient for competition binding studies, so no direct comparison of binding parameters with the neurointermediate lobe was possible here.
Chemical cross-linking of [ 125 I]GLP-1 to rat and human pituitary membranes
Incubation of human whole pituitary membranes with [ 125 I]GLP-1 followed by covalent attachment of the radiolabel to the binding protein component identified a single ligandbinding protein complex with a relative M r of 73,100 Ϯ 1,400 (n ϭ 4; Fig. 4 ). Subtracting 3,300 as the M r of GLP-1 gives a M r of 69,800 for the binding site. This band was not detectable, and therefore specific, when the incubations were carried out in the presence of 1 m unlabeled GLP-1. As shown in the representative autoradiograph (Fig. 4) , single labeled bands were also detected in samples from rat neurointermediate lobe, hypothalamic, and lung membranes, which were analyzed in parallel. Cross-linking with rat neurointermediate lobe and hypothalamic membranes showed apparently lower M r than that of human whole pituitary membranes, with the ligand-binding site complexes centered at M r of 59,300 Ϯ 100 and 58,100 Ϯ 900, respectively (n ϭ 3; Fig.  4A ), indicating M r for the binding site of 56,000 and 54,800, respectively. The M r of the ligand-binding site complex in rat lung was also lower than that in human lung (M r ϭ 56,600 Ϯ 900; n ϭ 3; Fig. 4B ), giving a M r of 53,300 for the binding site alone.
Effect of GLP-1 on cAMP in the rat neurointermediate lobe
To determine whether the rat neurointermediate lobe GLP-1-binding site is functionally coupled to the adenylyl cyclase system, the effects of GLP-1 on intracellular cAMP levels were examined ( Fig. 5 ; data expressed as a percentage of the control). The basal production of cAMP in the unstimulated rat neurointermediate lobe was 29 Ϯ 4 pmol/ neurointermediate lobe⅐15 min (n ϭ 4). GLP-1 at concentrations up to 1000 nm failed to stimulate cAMP formation in isolated rat neurointermediate lobes (1 nm, 33 Ϯ 6; 10 nm, 35 Ϯ 5; 1000 nm, 32 Ϯ 3 pmol/neurointermediate lobe⅐15 min; P ϭ NS; n ϭ 4 for all). Forskolin (100 m), used as a positive control, significantly stimulated cAMP production 12-fold to 352 Ϯ 47 pmol/neurointermediate lobe⅐15 min (P Ͻ 0.001 vs. basal; n ϭ 4). Having established that the GLP-1-binding site in the neurointermediate lobe does not appear to be functionally coupled to increases in cAMP, the effect of GLP-1 on intracellular cAMP levels increased by PACAP-(1-38), a known stimulator of cAMP in the posterior pituitary, was investigated in a second series of studies (Fig. 5) . In these studies the basal production of cAMP in the unstimulated neurointermediate lobe was 14 Ϯ 1 pmol/neurointermediate lobe⅐15 min (n ϭ 5). As shown in pmol/neurointermediate lobe⅐15 min; P ϭ NS; n ϭ 5 for both). PACAP-(1-38) stimulated cAMP levels at both concentrations tested (100 nm, 80 Ϯ 4; 1000 nm, 149 Ϯ 12 pmol/ neurointermediate lobe⅐15 min; P Ͻ 0.01; n ϭ 5 for both). Incubation of neurointermediate lobes with 100 nm PACAP-(1-38) and increasing concentrations of GLP-1 produced no significant potentiation or inhibition of PACAP-(1-38)-stimulated cAMP production (100 nm PACAP plus 10 nm GLP-1, 84 Ϯ 9; plus 100 nm GLP-1, 81 Ϯ 7; plus 1000 nm GLP-1, 91 Ϯ 11 pmol/neurointermediate lobe⅐15 min; P ϭ NS; n ϭ 5 for all).
Effect of GLP-1 on AVP and OT release in the rat neurointermediate lobe
We measured the release of AVP and OT in isolated rat neurointermediate lobes challenged with up to 1000 nm GLP-1 (Fig. 6 ). There was no significant effect of GLP-1 at any of the tested concentrations on AVP (Fig. 6A) or OT (Fig. 6B ) compared with unstimulated controls (control AVP release, 199 Ϯ 24 fmol/neurointermediate lobe⅐15 min; control OT release, 174 Ϯ 18 fmol/neurointermediate lobe⅐15 min). To determine whether release of posterior pituitary hormones could be stimulated, we depolarized the tissue using 56 mm K ϩ . In both experiments hormone release was greatly and significantly stimulated [AVP, 8,694 Ϯ 725 fmol/neurointermediate lobe⅐15 min (40 times basal); OT, 12,200 Ϯ 1,300 fmol/neurointermediate lobe⅐15 min (70 times basal); P Ͻ 0.001; n ϭ 6].
Discussion
In the present study we demonstrate for the first time GLP-1 binding in the human pituitary. Receptor autoradiography of GLP-1 binding in the human pituitary shows, like that in the rat pituitary, dense specific binding on the posterior lobe, with much weaker binding on the anterior lobe. GLP-1 radiolabel binding is strongly competed by unlabeled GLP-1 in both species. The low specific binding found in the anterior lobe of both human and rat pituitary may be related to thyrotrophs, which constitute only 5% of anterior pituitary cells (17) . These results are compatible with the previous study of the rat pituitary (31) . The equilibrium competition studies that we carried out in rat neurointermediate lobe membranes demonstrate that the binding of [
125 I]GLP-1 displays both high affinity and density. Analysis of the binding data identifies a single population of binding sites with a K d of 0.2 nm and a B max of 600 fmol/mg protein. This is different from the published observations (31) using quantitative autoradiography, which demonstrated the presence of high (3.4 pm) and lower (0.6 nm) affinity binding sites for GLP-1 in the rat neurointermediate lobe. The lower affinity binding site is very similar to that described here, but we could not detect any binding site with a K d of 3 pm. This high affinity site is of greater affinity than any value reported for GLP-1 receptors in the literature, but is only 1 order of magnitude greater than that reported by us in ␣TSH cells (28 pm), which is the next highest affinity for GLP-1 receptor binding. We used a concentration of 30 pm for the radioligand in our binding assays, making it technically difficult to detect a 3-pm affinity site; certainly, a label of extremely high specific activity would be required to achieve this sensitivity. The affinity of the rat neurointermediate lobe GLP-1-binding site is low compared with those detected by us in ␣TSH (28 pm) and GT 1 -7 (70 pm) cells (16, 17) , but lies within the range (0.3-2.5 nm for high affinity sites) reported in the literature for the other GLP-1-binding sites (40, 41) . The density of the rat neurointermediate lobe GLP-1-binding site is considerably higher than those detected in the literature (40, 41) or in ␣TSH (85 fmol/mg protein) and GT 1 -7 cells (160 fmol/mg protein) and is approximately equal to that detected in the rat lung, which expresses the highest previous density of binding (560 fmol/mg protein) (40) . We used whole human pituitary membrane because it is very difficult to distinguish by eye the posterior lobe from the anterior lobe in the frozen human pituitaries. Thus, the actual density of receptors, even taking into account receptors on, for example, thyrotroph cells, would be much higher in pure posterior lobe membranes. Certainly, if the human is similar to the rat in this study, there would be approximately 16 times higher binding in the neurointermediate lobe than in the anterior lobe. Specific binding of GLP-1 in human pituitary membranes is also inhibited in a concentration-dependent manner by exendin-4 and exendin-(9 -39). The affinity of exendin-4 (K i ϭ 2.6 nm), is similar to that of GLP-1 at the human pituitary binding site, and exendin-(9 -39) (K i ϭ 48 nm) displays lower affinity as expected (11) . These data are compatible with both the rat and human pituitary receptors being similar in binding properties to the cloned receptors.
Chemical cross-linking studies of human pituitary membranes for the first time reveal a single ligand-binding protein complex with a M r of 73,000. This value is higher than those previously reported for GLP-1 receptors on human ␤-cell membranes (M r ϭ 63,000) (42) . Single labeled bands are also detected in the rat neurointermediate lobe (M r ϭ 59,300), hypothalamic (M r ϭ 58,100), and lung membranes (M r ϭ 56,600). These values are apparently lower than those in human pituitary membranes. GLP-1 receptor messenger RNA transcripts have been identified in human pancreas, lung, kidney, stomach, heart, and brain by ribonuclease pro- 1 and 2) , human whole pituitary membranes (lanes 3, 4, 7, and 8), and rat neurointermediate lobe membranes (lanes 5 and 6); and B) cross-linking of receptor-ligand complexes in rat hypothalamic membranes (lanes 1 and 2), human whole pituitary membranes (lanes 3, 4, 7, and 8), and rat lung membranes (lanes 5 and 6). The relative M r (ϫ10 Ϫ3 ) of the protein standards is shown on the left of the figure. Protein standards are: myosin, 205,000; ␤-galactosidase, 116,000; phosphorylase b, 97,000; BSA, 66,000; and ovalbumin, 45,000. The autoradiographs were exposed for 4 days at Ϫ80 C.
FIG. 5.
The effect of GLP-1 on cAMP levels in isolated rat neurointermediate lobes. cAMP levels were assayed in rat neurointermediate lobes by RIA of acid-ethanol extracts as described in Materials and Methods. All experiments were performed in the presence of 2 mM IBMX. The results are expressed as a percentage of the control levels. Shown are the effects of 100 plus 1000 nM GLP-1, and 100 plus 1000 nM PACAP-(1-38) on cAMP compared with forskolin (100 M) as a positive control and 10, 100 plus 1000 nM GLP-1 on neurointermediate lobe cAMP levels stimulated by PACAP-(1-38) 8 (100 nM). Forskolin and both concentrations of PACAP-(1-38) significantly stimulated cAMP levels[(P Ͻ 0.001 for forskolin; P Ͻ 0.01 for PACAP-(1-38); n ϭ 6]. There was no significant difference in cAMP levels between PACAP-(1-38) (100 nM) and PACAP-(1-38) plus any concentration of GLP-1.
tection analyses, and GLP-1 receptors in human pancreas, heart, and brain (which is the site of synthesis of posterior pituitary receptors on neurons) have the same amino acid sequences (43) . The most likely explanation for the species and tissue variations in receptor M r in cross-linking experiments is differential glycosylation (44) . To determine this, deglycosylation protocols need to be employed in the crosslinking experiments and then M r values compared (45) . We have been able to show that the deglycosylated rat neurointermediate lobe binding site has a M r of 50,000, but could not generate similar data for the human pituitary binding site (results not shown).
To investigate whether this GLP-1-binding site is functionally coupled to a second messenger system, we first measured cAMP accumulation in the rat neurointermediate lobe, as G s coupling is the preferred coupling of the cloned receptor in both man and rat (9, 10) . Previously, it was demonstrated that GLP-1 stimulates cAMP generation in tissue homogenates of rat whole pituitary gland, although in this study the GLP-1-36 amide peptide was used, which is now thought to be inactive (46) . On the contrary, in the present study GLP-1 at concentrations up to 1 m failed to stimulate or inhibit cAMP production in the rat neurointermediate lobe. This may imply that the effects of GLP-1 on cAMP generation are restricted to the anterior pituitary. Hence, it appears that in the neurointermediate lobe the GLP-1-binding site is not functionally coupled to increases in cAMP and adenylyl cyclase activity, so this binding site could be functionally different from that of the cloned receptors. Furthermore, GLP-1 had no effect on PACAP-stimulated cAMP production in the rat neurointermediate lobe. The lack of an inhibitory effect on basal cAMP also differs from some reports of novel GLP-1 receptors in adipose and muscle tissues (22, 23) , but is in agreement with others (20, 21) .
It is of course possible that the GLP-1 receptors described here are nonfunctional clearance receptors. However, neuroendocrine tissue would be a very unusual site for such clearance receptors, and although the density of binding is very high, the small size of the neurointermediate lobe would make such a role problematical compared with, for example, lung, which expresses both high density and high numbers of GLP-1 receptors. Thus, the neurointermediate lobe receptors may be functional, but their signaling pathways were beyond the scope of this study. GLP-1 signaling in primary islet cultures, ␤-cell lines, cells transfected with the GLP-1 receptor complementary DNA, and the brain has been shown to be functionally coupled to both activation of adenylyl cyclase (47, 48) and phospholipase C pathways (14, 49) . GLP-1 binding is associated with an increase in cytosolic free calcium (50) and may increase intracellular calcium via activation of a prolonged cAMP-sensitive inward current, leading to membrane depolarization and increases in intracellular calcium (13) . It remains to be investigated whether neurointermediate lobe GLP-1 receptors are coupled to decreases in cAMP in the absence of IBMX or increases in calcium and phospholipase C activity. However, effects on intracellular calcium levels are usually seen together with cAMP increases (13, 14, 49) .
The obvious question posed by these results is what is the role of the extremely high density of GLP-1 receptors on the neurointermediate lobe? The results of Zueco et al. (34) indicate a very small effect of GLP-1 on basal OT release (ϳ25% increase) and no effect on basal AVP release. We performed similar static culture secretion experiments, and in agreement with Zueco et al. we were unable to show any direct effect of GLP-1 (1-1000 nm) on AVP secretion. However, we could also show no effect on OT secretion. Both hormones were released by K ϩ (56 mm) stimulation. GLP-1 has been found to alter water intake and can have effects on plasma AVP when injected icv. However, it does seem unlikely that these effects are mediated via a direct interaction with neurointermediate lobe GLP-1 receptors.
We have successfully demonstrated the presence of high density, specific binding sites for GLP-1 on the posterior/ neurointermediate lobe of human and rat pituitary gland. These sites have similar binding characteristics and mol wt as other reported GLP-1 receptors even though there are some minor differences among them. Although we have been unable to assign a second messenger system or function to these GLP-1-binding sites, it seems highly likely that they do exist. The similarity in binding properties to the cloned receptors but differences in G protein coupling could indicate a modified C-terminal part of the receptor, perhaps even a splice variant. The autoradiographical methods presented FIG. 6 . The effect of GLP-1 on basal AVP and OT release in isolated rat neurointermediate lobes. AVP and OT release were measured as described in Materials and Methods. All results are expressed as a percentage of control basal levels for AVP (A) and OT (B). There was no effect of GLP-1 on the release of either hormone compared with controls, but in both cases 56 mM K ϩ stimulated release (*, P Ͻ 0.001; n ϭ 6).
do not reveal a morphological localization of the GLP-1-binding sites, so it remains to be determined whether they are associated with nerve terminals, pituicytes, or capillaries. Perhaps these GLP-1-binding sites have a role to play at the level of the pituicytes, modulating neuron-glia interaction.
